Pfizer said its pneumonia vaccine Prevnar 13 met both the main and secondary goals of a post-approval 85,000-patient trial, one of the largest drug studies ever conducted. Data showed that the vaccine prevented a first episode of community-acquired pneumonia and a first episode of invasive bloodstream infections in people 65 and older. The trial's success could boost the vaccine's sales by $1 billion or more, analysts said.

Related Summaries